Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.

McEntee G, Kyula JN, Mansfield D, Smith H, Wilkinson M, Gregory C, Roulstone V, Coffey M, Harrington KJ.

Oncotarget. 2016 Jul 1. doi: 10.18632/oncotarget.10365. [Epub ahead of print]

2.

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.

Ungerechts G, Bossow S, Leuchs B, Holm PS, Rommelaere J, Coffey M, Coffin R, Bell J, Nettelbeck DM.

Mol Ther Methods Clin Dev. 2016 Apr 6;3:16018. doi: 10.1038/mtm.2016.18. eCollection 2016. Review.

3.

Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.

Igase M, Hwang CC, Kambayashi S, Kubo M, Coffey M, Miyama TS, Baba K, Okuda M, Noguchi S, Mizuno T.

Can J Vet Res. 2016 Jan;80(1):21-31.

4.

Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.

Villalona-Calero MA, Lam E, Otterson GA, Zhao W, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV.

Cancer. 2016 Mar 15;122(6):875-83. doi: 10.1002/cncr.29856. Epub 2015 Dec 28.

PMID:
26709987
5.

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K, Coffey M, Melcher A, Vile R.

Mol Ther. 2016 Feb;24(1):166-74. doi: 10.1038/mt.2015.156. Epub 2015 Aug 27.

PMID:
26310630
6.

The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.

Mahalingam D, Patel S, Nuovo G, Gill G, Selvaggi G, Coffey M, Nawrocki ST.

BMC Cancer. 2015 Jul 10;15:513. doi: 10.1186/s12885-015-1518-0.

7.

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.

Parrish C, Scott GB, Migneco G, Scott KJ, Steele LP, Ilett E, West EJ, Hall K, Selby PJ, Buchanan D, Varghese A, Cragg MS, Coffey M, Hillmen P, Melcher AA, Errington-Mais F.

Leukemia. 2015 Sep;29(9):1799-810. doi: 10.1038/leu.2015.88. Epub 2015 Mar 27.

8.

The oncolytic virus, pelareorep, as a novel anticancer agent: a review.

Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M.

Invest New Drugs. 2015 Jun;33(3):761-74. doi: 10.1007/s10637-015-0216-8. Epub 2015 Feb 19. Review.

PMID:
25693885
9.

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ.

Mol Ther. 2015 May;23(5):931-42. doi: 10.1038/mt.2015.15. Epub 2015 Jan 26.

10.

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.

Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J.

Clin Cancer Res. 2015 Mar 15;21(6):1305-12. doi: 10.1158/1078-0432.CCR-14-1770. Epub 2014 Nov 25.

11.

Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A, Vile R.

Mol Ther. 2014 Oct;22(10):1851-63. doi: 10.1038/mt.2014.118. Epub 2014 Jun 24.

12.

Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM.

Mol Ther. 2014 May;22(5):1056-62. doi: 10.1038/mt.2014.21. Epub 2014 Feb 20.

13.

Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production.

Chakrabarty R, Tran H, Fortin Y, Yu Z, Shen SH, Kolman J, Onions D, Voyer R, Hagerman A, Serl S, Kamen A, Thompson B, Coffey M.

Appl Microbiol Biotechnol. 2014 Feb;98(4):1763-70. doi: 10.1007/s00253-013-5499-0. Epub 2014 Jan 14.

PMID:
24419798
14.

The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.

Kapadia R, Coffey MC.

Methods. 2010 Dec;52(4):301-6. doi: 10.1016/j.ymeth.2010.08.011. Epub 2010 Aug 27. Review.

PMID:
20801221
Items per page

Supplemental Content

Loading ...
Write to the Help Desk